SLR Metaliks, a leading supplier of alloy steel to automobile industry, is planning its production in expectation of a "V-shaped growth" by vehicle manufacturers and has not held back capacity enhancement during the lockdown, according to a top company official.
The company, which supplies to original equipment manufacturers (OEMs) including Tata Motors, Daimler, Mahindra, Swaraz Mazda and Bajaj Auto, among others, is expecting recovery in demand from auto sector from September onwards and reach "pre-COVID levels" by December provided there are no further lockdowns and worsening of the coronavirus pandemic.
"OEMs are talking about a V-shaped growth as the tractor industry is doing very well now. Whenever there is a boom in the tractor industry, it means the agri sector is doing very well. It results in robust demand in two-wheeler and entry-level cars," SLR Metaliks Managing Director Rajkumar Goel told PTI.
While April sales were zero, in May it was almost 20 per cent and in June it reached near about 50 percent in the auto sector, he added.
"We are expecting July to be around 50-60 percent...You leave out the second quarter, after that it will be good provided there is no lockdown again or the coronavirus pandemic doesn't worsen. From September onwards and by the time we reach December we will reach pre-COVID levels. We are fully prepared to meet the expected demand." Goel said.
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
When asked if the company has changed its investment and expansion plans due to COVID-19, he replied in the negative.
"We have utilised the lockdown to carry out our expansion plans. Our existing capacity is 3 lakh tonnes per annum and we are enhancing it to 4 lakh tonnes per annum, an increase of 33 percent...We are investing Rs 60 crore for the same. The fresh capacity will be available by August 10," Goel said.
The company's manufacturing plant is located at Hospet in Karnataka and almost 99 percent of its production is for domestic consumption.
On the financial impact of the health crisis, he said, "There is recovery of the topline but bottomline will be a struggle. Today we are not talking about the bottomline. Our priority is on topline. If the industry is functioning and if we are able to sell our products, we will be able to take care of bottomline although it may be up or down a bit."Last fiscal, the company had posted a turnover of over Rs 1,200 crore.